Fatty Liver News and Research

Latest Fatty Liver News and Research

Fatty liver disease linked to higher risk of heart attacks

Researchers at Mass General Brigham Heart and Vascular Institute found that people with hepatic steatosis, commonly called "fatty liver disease," have a higher amount of noncalcified, rupture-prone coronary plaque and face nearly twice the rate of cardiovascular events compared to those without steatosis.

20 May 2026

Global consortium renames polycystic ovary syndrome to reflect science

First, it was named after two men. Then, it was named for a false premise. Now, after more than a century, one of the most common hormone disorders affecting women worldwide has a name that reflects the science.

18 May 2026

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

New imaging technique maps 38000 liver cells to solve fibrosis

The liver is often called a "silent organ," as it can sustain significant damage without obvious symptoms. But when injury is prolonged, whether from alcohol, poor diet, or chronic hepatitis virus infection, it triggers fibrosis: a progressive hardening and scarring of liver tissue.

14 May 2026

Urges for cardiologists to screen patients for UPF intake

The European Society of Cardiology identifies ultra-processed foods as a key cardiovascular risk, urging a shift in dietary guidelines for better heart health.

11 May 2026

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

Advanced heart, kidney and metabolic disease linked to higher cancer risk

People with advanced heart, kidney and metabolic disease may face a higher risk of developing cancer, according to new research published today in the American Heart Association's peer-reviewed scientific journal Circulation: Population Health and Outcomes.

27 Apr 2026

Prediabetes leaves lasting fat tissue changes after bariatric surgery

Prediabetes may leave a lasting molecular "footprint" on adipose (fat) tissue which appears to make maintaining weight loss after bariatric surgery more difficult, according to new research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

22 Apr 2026

Immune cell interactions drive liver inflammation and fibrosis

When the liver is injured - for example, due to bile accumulation - immune cells become activated. In mouse experiments, the Würzburg team observed that certain immune cells undergo functional changes in response to liver damage, adopting a highly pro-inflammatory state.

21 Apr 2026

Eating oranges daily may shift lipid patterns in fatty liver disease

A 4-week trial on 'Navelina' oranges shows potential effects on lipid metabolism in fatty liver disease, revealing intriguing but non-significant patterns.

20 Apr 2026

Researchers discover a molecular signature to flag dysfunctional aging cells

UCLA researchers have identified a rogue population of immune cells that quietly accumulates in aging tissues and in the livers of people with fatty liver disease. Clearing these cells, they found, dramatically reduced inflammation and reversed liver damage in mice - even while the animals remained on an unhealthy diet.

16 Apr 2026

Gut-liver changes drive foodborne infection severity in fatty liver disease

A research team led by the University of California, Irvine's Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.

15 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Waist-to-height ratio outperforms BMI in predicting hypertension risk

New waist-to-height cut-offs to assess fat mass and obesity predicted the risk of hypertension better than body mass index, according to a new study from the University of Eastern Finland and the Robert Wood Johnson Medical School at Rutgers University in the US.

14 Apr 2026

Weight gain timing affects long-term health outcomes

When in life we gain weight can have a significant impact on our health many years later. In a study involving over 600,000 people, researchers at Lund University in Sweden have investigated how changes in weight between the ages of 17 and 60 are linked to the risk of dying from various diseases

11 Apr 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

29 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026